Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Tucson, Arizona 85724


Purpose:

To estimate the percent of patients with myelodysplastic syndromes (MDS) who experience erythroid response and the interval to response with daily treatment of 25 mg of CC-5013 .


Criteria:

- Diagnosis of de novo myelodysplastic syndrome of at least 12 weeks duration. - Baseline mean hemoglobin < 10.0 g/dL (untransfused) and/or be transfusion dependent defined by requiring at least 4 units of RBC in the 8 weeks prior to baseline. - More than 30 days must have elapsed since any previous treatment for MDS, other than transfusion. - Women must not be pregnant or lactating - No use of another experimental study drug within 30 dy\ays of baseline - Understand and sign written informed consent - Able to adhere to study visit schedule, understand and comply with other protocol requirements.


NCT ID:

NCT00044382


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Tucson, Arizona 85724
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 14, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.